Sort
16,179 grants matching “malaria”
Structural Genomics of Pathogenic Protozoa
$7,056,491University Of Washington · P50 · FY2004 · GM
Tafenoquine, A New Drug for Malaria Prevention &Control
$7,031,061Glaxosmithkline · UC1 · FY2000 · AI
XIX International AIDS Conference (AIDS 2012)
$7,010,000Chris Beyrer · Ias · R13 · FY2011 · AI
CoVPN 3008 A Phase 3, Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
$7,007,011Judith S. Currier · University Of California Los Angeles · UM1 · FY2022 · AI
Vaccine Immunology Program
$6,981,494Sarah Andrews · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
TULANE NATINAL PRIMATE RESEARCH CENTER
$6,979,186Tulane University Of Louisiana · P51 · FY2005 · RR
Vaccine Immunology Program
$6,901,965Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
MALARIA VACCINE PRODUCTION AND SUPPORT SERVICES
$6,899,135Kathleen Kootz · Science Applications International Corp · N01 · FY2011 · AI
Malaria Vaccines: Pfs25-rEPA and Pfs230-rEPA
$6,889,173Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
A once-weekly oral methadone for maintenance therapy for opioid use disorder
$6,854,394Stephen Zale · Lyndra Therapeutics, Inc. · UG3 · FY2019 · DA
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)
$6,820,430Mark Joseph Mulligan · New York University School Of Medicine · UM1 · FY2021 · AI
Infectious Disease Genomics: Pathogen Evolution, Emergence, and Host Interaction
$6,794,965Bruce W. Birren · Broad Institute, Inc. · U19 · FY2015 · AI
Malaria Vaccines: Pfs25-rEPA and Pfs230-rEPA
$6,665,131Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
The J. Craig Venter Institute Genome Center for Infectious Diseases
$6,568,797William Charles Nierman · J. Craig Venter Institute, Inc. · U19 · FY2016 · AI
CoVPN 3002 A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222 for the Prevention of COVID-19 LAB
$6,554,653Margaret Juliana McElrath · Fred Hutchinson Cancer Research Center · UM1 · FY2020 · AI
Malaria Vaccines: Pfs25-rEPA and Pfs230-rEPA
$6,535,818Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Malaria Vaccines: Pfs25-rEPA and Pfs230-rEPA
$6,509,799Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
DCTD Biopharmaceutical Development
$6,449,441David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2016 · CA
Malaria Vaccines: Pfs25-rEPA and Pfs230-rEPA
$6,432,150Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Infectious Disease Genomics: Pathogen Evolution, Emergence, and Host Interaction
$6,408,353Bruce W. Birren · Broad Institute, Inc. · U19 · FY2016 · AI
DCTD Biopharmaceutical Development
$6,373,511David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2015 · CA
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)
$6,372,793David S Stephens · Emory University · UM1 · FY2021 · AI
GH21-003, Advancing Public Health Research in Kenya
$6,329,348M Kariuki Njenga · Washington State University · U01 · FY2021 · GH
GH21-003, Advancing Public Health Research in Kenya
$6,288,488M Kariuki Njenga · Washington State University · U01 · FY2025 · GH
The J. Craig Venter Institute Genome Center for Infectious Diseases
$6,200,723William Charles Nierman · J. Craig Venter Institute, Inc. · U19 · FY2015 · AI